{"id":"cggv:9cf90ec8-f2fd-4b93-89ca-d20e628a6109v1.2","type":"EvidenceStrengthAssertion","calculatedEvidenceStrength":"Definitive","contributions":[{"id":"cggv:9cf90ec8-f2fd-4b93-89ca-d20e628a6109_contrib","agent":"http://dataexchange.clinicalgenome.org/agent/10107","date":"2024-10-31T16:00:00.000Z","role":"Approver"},{"id":"cggv:9cf90ec8-f2fd-4b93-89ca-d20e628a6109_publish_contrib","agent":"http://dataexchange.clinicalgenome.org/agent/10107","date":"2024-10-31T18:18:07.658Z","role":"Publisher"}],"curationReasons":{"id":"cg:DiseaseNameUpdate"},"evidence":[{"id":"cggv:9cf90ec8-f2fd-4b93-89ca-d20e628a6109_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:7f8f26ed-70ea-438c-b4eb-37da1c154ea4_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:7f8f26ed-70ea-438c-b4eb-37da1c154ea4","type":"Proband","ageType":"AgeAtReport","ageUnit":"Years","ageValue":15,"allele":[{"id":"cggv:12a4f790-a00a-43e6-8386-7ee0cf910ff9","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001111.5(ADAR):c.577C>G (p.Pro193Ala)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA345491"}},{"id":"cggv:f8a7cd83-9cb0-4263-9798-a770f1b88331","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001111.5(ADAR):c.2608G>A (p.Ala870Thr)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA343775"}}],"detectionMethod":"Rice et al. used massively parallel sequencing of exomes for probands AGS81_P1 and AGS219 and found variants in ADAR. Then sequenced ADAR in other individuals lacking variants in TREX1, RNASEH2B, RNASEH2C, RNASEH2A and SAMHD1. ","firstTestingMethod":"Other","phenotypes":["obo:HP_0002514","obo:HP_0011344","obo:HP_0000737","obo:HP_0000007","obo:HP_0002415"],"sex":"Male","variant":[{"id":"cggv:a21f5a2b-e6a4-41d2-bfad-000a13e64e2e_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:12a4f790-a00a-43e6-8386-7ee0cf910ff9"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/23001123","type":"dc:BibliographicResource","dc:abstract":"Adenosine deaminases acting on RNA (ADARs) catalyze the hydrolytic deamination of adenosine to inosine in double-stranded RNA (dsRNA) and thereby potentially alter the information content and structure of cellular RNAs. Notably, although the overwhelming majority of such editing events occur in transcripts derived from Alu repeat elements, the biological function of non-coding RNA editing remains uncertain. Here, we show that mutations in ADAR1 (also known as ADAR) cause the autoimmune disorder Aicardi-Goutières syndrome (AGS). As in Adar1-null mice, the human disease state is associated with upregulation of interferon-stimulated genes, indicating a possible role for ADAR1 as a suppressor of type I interferon signaling. Considering recent insights derived from the study of other AGS-related proteins, we speculate that ADAR1 may limit the cytoplasmic accumulation of the dsRNA generated from genomic repetitive elements.","dc:creator":"Rice GI","dc:date":"2012","dc:title":"Mutations in ADAR1 cause Aicardi-Goutières syndrome associated with a type I interferon signature."}},{"id":"cggv:86643a22-9a83-49c8-97af-bae0b0ec1188_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:f8a7cd83-9cb0-4263-9798-a770f1b88331"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/23001123"}],"rdfs:label":"Rice_AGS93"},{"id":"cggv:a21f5a2b-e6a4-41d2-bfad-000a13e64e2e","type":"obo:SEPIO_0004097","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:a21f5a2b-e6a4-41d2-bfad-000a13e64e2e_variant_evidence_item"},{"id":"cggv:a21f5a2b-e6a4-41d2-bfad-000a13e64e2e_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"Yes","dc:description":"Mannion et al. 2014 (PMID: 25456137) found that ADAR p110 and p150 isoform mutants P193A, A870T, R892H, K999N, G1007R, and D1113H expressed in HEK293T cells exhibit a significant decrease in editing activity relative to WT"}],"strengthScore":0.5},{"id":"cggv:86643a22-9a83-49c8-97af-bae0b0ec1188","type":"obo:SEPIO_0004097","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:86643a22-9a83-49c8-97af-bae0b0ec1188_variant_evidence_item"},{"id":"cggv:86643a22-9a83-49c8-97af-bae0b0ec1188_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"Yes","dc:description":"Mannion et al. 2014 (PMID: 25456137) found that ADAR p110 and p150 isoform mutants P193A, A870T, R892H, K999N, G1007R, and D1113H expressed in HEK293T cells exhibit a significant decrease in editing activity relative to WT"}],"strengthScore":0.5}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:940ff4f6-0c03-4d75-a6ca-06e07807b598_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:940ff4f6-0c03-4d75-a6ca-06e07807b598","type":"Proband","allele":[{"id":"cggv:28fae0a1-0bda-4f00-b964-648d52070852","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001111.5(ADAR):c.2565_2568del (p.Asn857AlafsTer17)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA526666269"}},{"id":"cggv:12a4f790-a00a-43e6-8386-7ee0cf910ff9"}],"detectionMethod":"Sanger sequencing of ADAR was performed on patients","firstTestingMethod":"Sanger sequencing","phenotypes":["obo:HP_0002063","obo:HP_0000007","obo:HP_0002514","obo:HP_0002376"],"sex":"UnknownEthnicity","variant":[{"id":"cggv:e316fa2b-e1d7-48f8-9e67-069de7bc454d_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:28fae0a1-0bda-4f00-b964-648d52070852"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/24262145","type":"dc:BibliographicResource","dc:abstract":"We recently observed mutations in ADAR1 to cause a phenotype of bilateral striatal necrosis (BSN) in a child with the type I interferonopathy Aicardi-Goutières syndrome (AGS). We therefore decided to screen patients with apparently non-syndromic BSN for ADAR1 mutations, and for an upregulation of interferon-stimulated genes (ISGs).","dc:creator":"Livingston JH","dc:date":"2014","dc:title":"A type I interferon signature identifies bilateral striatal necrosis due to mutations in ADAR1."}},{"id":"cggv:5637d715-e83e-420c-bc19-db5c78e7bfff_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:12a4f790-a00a-43e6-8386-7ee0cf910ff9"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/24262145"}],"rdfs:label":"Livingston_5"},{"id":"cggv:e316fa2b-e1d7-48f8-9e67-069de7bc454d","type":"obo:SEPIO_0004097","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"cggv:e316fa2b-e1d7-48f8-9e67-069de7bc454d_variant_evidence_item"}],"strengthScore":1.5},{"id":"cggv:5637d715-e83e-420c-bc19-db5c78e7bfff","type":"obo:SEPIO_0004097","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:5637d715-e83e-420c-bc19-db5c78e7bfff_variant_evidence_item"},{"id":"cggv:5637d715-e83e-420c-bc19-db5c78e7bfff_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"Yes","dc:description":"Mannion et al. 2014 (PMID: 25456137) found that ADAR p110 and p150 isoform mutants P193A, A870T, R892H, K999N, G1007R, and D1113H expressed in HEK293T cells exhibit a significant decrease in editing activity relative to WT"}],"strengthScore":0.5}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:4d1963cb-6848-45dc-aa24-3c5399fc6e76_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:4d1963cb-6848-45dc-aa24-3c5399fc6e76","type":"Proband","ageType":"AgeAtReport","ageUnit":"Years","ageValue":15,"allele":{"id":"cggv:a875013c-d815-4257-aabd-9b68f5d00452","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001111.5(ADAR):c.3337G>C (p.Asp1113His)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA343777"}},"detectionMethod":"Rice et al. used massively parallel sequencing of exomes for probands AGS81_P1 and AGS219 and found variants in ADAR. Then sequenced ADAR in other individuals lacking variants in TREX1, RNASEH2B, RNASEH2C, RNASEH2A and SAMHD1. ","firstTestingMethod":"Other","phenotypes":["obo:HP_0000007","obo:HP_0000252","obo:HP_0011344","obo:HP_0002514","obo:HP_0002415","obo:HP_0011968"],"sex":"Female","variant":{"id":"cggv:081aa0f8-2570-4962-b4bf-ac2f6283cf72_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:a875013c-d815-4257-aabd-9b68f5d00452"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:Homozygous"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/23001123"},"rdfs:label":"Rice_AGS107"},{"id":"cggv:081aa0f8-2570-4962-b4bf-ac2f6283cf72","type":"obo:SEPIO_0004097","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:081aa0f8-2570-4962-b4bf-ac2f6283cf72_variant_evidence_item"},{"id":"cggv:081aa0f8-2570-4962-b4bf-ac2f6283cf72_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"Yes","dc:description":"Mannion et al. 2014 (PMID: 25456137) found that ADAR p110 and p150 isoform mutants P193A, A870T, R892H, K999N, G1007R, and D1113H expressed in HEK293T cells exhibit a significant decrease in editing activity relative to WT"}],"strengthScore":0.5}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:08526296-08da-4e1e-ac27-1b51b7b8c971_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:08526296-08da-4e1e-ac27-1b51b7b8c971","type":"Proband","allele":[{"id":"cggv:c5ec24f4-8a69-4215-8880-d1c8bfeeabf7","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001111.5(ADAR):c.2515del (p.Thr839ProfsTer6)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA2586963874"}},{"id":"cggv:532fd7c0-2d4f-4cf2-b4f0-bf301dd75bd8","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001111.5(ADAR):c.518A>G (p.Asn173Ser)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA1131690"}}],"detectionMethod":"Sanger sequencing of ADAR was performed on patients","firstTestingMethod":"Sanger sequencing","phenotypes":["obo:HP_0001332","obo:HP_0002514","obo:HP_0000007","obo:HP_0011344"],"sex":"UnknownEthnicity","variant":[{"id":"cggv:f83131c6-ed5b-4545-b055-34dd5d17ee5b_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:c5ec24f4-8a69-4215-8880-d1c8bfeeabf7"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/24262145"},{"id":"cggv:355357e4-db9d-419a-baba-3094548b6fbc_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:532fd7c0-2d4f-4cf2-b4f0-bf301dd75bd8"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/24262145"}],"rdfs:label":"Livingston_2"},{"id":"cggv:355357e4-db9d-419a-baba-3094548b6fbc","type":"obo:SEPIO_0004097","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"cggv:355357e4-db9d-419a-baba-3094548b6fbc_variant_evidence_item"}],"strengthScore":0.1},{"id":"cggv:f83131c6-ed5b-4545-b055-34dd5d17ee5b","type":"obo:SEPIO_0004097","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"cggv:f83131c6-ed5b-4545-b055-34dd5d17ee5b_variant_evidence_item"}],"strengthScore":1.5}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:fb64260f-1165-4ddb-af97-0eb1d66213d5_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:fb64260f-1165-4ddb-af97-0eb1d66213d5","type":"Proband","ageType":"AgeAtReport","ageUnit":"Years","ageValue":4,"allele":[{"id":"cggv:21f81395-b582-4876-8305-9064a3faba14","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001111.5(ADAR):c.1076_1080del (p.Lys359ArgfsTer14)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA130318"}},{"id":"cggv:12a4f790-a00a-43e6-8386-7ee0cf910ff9"}],"detectionMethod":"Rice et al. used massively parallel sequencing of exomes for probands AGS81_P1 and AGS219 and found variants in ADAR. Then sequenced ADAR in other individuals lacking variants in TREX1, RNASEH2B, RNASEH2C, RNASEH2A and SAMHD1. ","firstTestingMethod":"Other","phenotypes":["obo:HP_0011344","obo:HP_0002514","obo:HP_0000252","obo:HP_0000737","obo:HP_0000007","obo:HP_0011968"],"sex":"Male","variant":[{"id":"cggv:d217a60d-0ee2-4534-99de-cb92a62223ff_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:12a4f790-a00a-43e6-8386-7ee0cf910ff9"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/23001123"},{"id":"cggv:2c6c0f12-406c-42a6-ba15-e40d7a9b4317_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:21f81395-b582-4876-8305-9064a3faba14"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/23001123"}],"rdfs:label":"Rice_AGS327"},{"id":"cggv:d217a60d-0ee2-4534-99de-cb92a62223ff","type":"obo:SEPIO_0004097","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:d217a60d-0ee2-4534-99de-cb92a62223ff_variant_evidence_item"},{"id":"cggv:d217a60d-0ee2-4534-99de-cb92a62223ff_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"Yes","dc:description":"Mannion et al. 2014 (PMID: 25456137) found that ADAR p110 and p150 isoform mutants P193A, A870T, R892H, K999N, G1007R, and D1113H expressed in HEK293T cells exhibit a significant decrease in editing activity relative to WT"}],"strengthScore":0.5},{"id":"cggv:2c6c0f12-406c-42a6-ba15-e40d7a9b4317","type":"obo:SEPIO_0004097","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"cggv:2c6c0f12-406c-42a6-ba15-e40d7a9b4317_variant_evidence_item"}],"strengthScore":1.5}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:9cf90ec8-f2fd-4b93-89ca-d20e628a6109_ar_el","type":"EvidenceLine","specifiedBy":"GeneValidityOverallAutosomalRecessiveVariantEvidenceCriteria","strengthScore":12},{"id":"cggv:00f48ffd-af73-4172-a92a-edb6ae5ea78a_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:00f48ffd-af73-4172-a92a-edb6ae5ea78a","type":"Proband","ageType":"AgeAtDeath","ageUnit":"Months","ageValue":10,"allele":{"id":"cggv:d2d3f13b-e005-4232-98f3-894624855656","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001111.5(ADAR):c.3019G>A (p.Gly1007Arg)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA130316"}},"detectionMethod":"Rice et al. used massively parallel sequencing of exomes for probands AGS81_P1 and AGS219 and found variants in ADAR. Then sequenced ADAR in other individuals lacking variants in TREX1, RNASEH2B, RNASEH2C, RNASEH2A and SAMHD1. ","firstTestingMethod":"Other","phenotypes":["obo:HP_0000007","obo:HP_0001511","obo:HP_0002240","obo:HP_0002514","obo:HP_0001744","obo:HP_0002415","obo:HP_0001873","obo:HP_0011344"],"sex":"Female","variant":{"id":"cggv:a8623470-ef6f-4208-a337-1071c558fe6b_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:d2d3f13b-e005-4232-98f3-894624855656"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:Homozygous"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/23001123"},"rdfs:label":"Rice_AGS228"},{"id":"cggv:a8623470-ef6f-4208-a337-1071c558fe6b","type":"obo:SEPIO_0004097","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:a8623470-ef6f-4208-a337-1071c558fe6b_variant_evidence_item"},{"id":"cggv:a8623470-ef6f-4208-a337-1071c558fe6b_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"Yes","dc:description":"Mannion et al. 2014 (PMID: 25456137) found that ADAR p110 and p150 isoform mutants P193A, A870T, R892H, K999N, G1007R, and D1113H expressed in HEK293T cells exhibit a significant decrease in editing activity relative to WT"}],"strengthScore":0.5}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:96fafcaf-0b1d-441f-a999-14d67241299d_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:96fafcaf-0b1d-441f-a999-14d67241299d","type":"Proband","ageType":"AgeAtReport","ageUnit":"Years","ageValue":14,"allele":[{"id":"cggv:12a4f790-a00a-43e6-8386-7ee0cf910ff9"},{"id":"cggv:a04e2ccd-048b-4dcf-ad20-e9c47845b8eb","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001111.5(ADAR):c.1A>G (p.Met1Val)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA342612306"}}],"detectionMethod":"Panel sequencing using enrichment of coding exons of 4813 genes associated with known clinical phenotypes revealed two heterozygous mutations in ADAR ","firstTestingMethod":"Other","phenotypes":["obo:HP_0002376","obo:HP_0001332","obo:HP_0002273","obo:HP_0002514","obo:HP_0001252","obo:HP_0001263","obo:HP_0000007","obo:HP_0001298"],"sex":"Female","variant":[{"id":"cggv:6cabdaaf-da1c-45c5-9776-66935a54569d_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:a04e2ccd-048b-4dcf-ad20-e9c47845b8eb"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/29221912","type":"dc:BibliographicResource","dc:abstract":"Aicardi-Goutières syndrome (AGS) is a hereditary inflammatory encephalopathy resulting in severe neurological damage in the majority of cases. We report on two siblings with AGS6 due to compound heterozygosity for a known and a novel mutation in the ADAR gene and a strikingly variable phenotype. The first sibling presented at 12 months of age with a subacute encephalopathy following a mild respiratory infection. The child developed a spastic tetraparesis, generalized dystonia and dysarthria. In contrast, the younger sibling presented with an acute episode of neurological impairment in his third year of life, from which he recovered without sequelae within a few weeks. These findings illustrate a striking intrafamilial phenotypic variability in patients with AGS6 and describe the first case of a full recovery from an acute encephalopathy in an AGS patient. Our findings also suggest that AGS should be considered as an important differential diagnosis of an infection-triggered encephalopathy in infancy despite the absence of typical neuroimaging findings.","dc:creator":"Schmelzer L","dc:date":"2018","dc:title":"Variable clinical phenotype in two siblings with Aicardi-Goutières syndrome type 6 and a novel mutation in the ADAR gene."}},{"id":"cggv:53a3fc15-474b-4e79-9d83-29a559c5fc82_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:12a4f790-a00a-43e6-8386-7ee0cf910ff9"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/29221912"}],"rdfs:label":"Schmelzer_Case 1"},{"id":"cggv:53a3fc15-474b-4e79-9d83-29a559c5fc82","type":"obo:SEPIO_0004097","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:53a3fc15-474b-4e79-9d83-29a559c5fc82_variant_evidence_item"},{"id":"cggv:53a3fc15-474b-4e79-9d83-29a559c5fc82_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"Yes","dc:description":"Mannion et al. 2014 (PMID: 25456137) found that ADAR p110 and p150 isoform mutants P193A, A870T, R892H, K999N, G1007R, and D1113H expressed in HEK293T cells exhibit a significant decrease in editing activity relative to WT"}],"strengthScore":0.5},{"id":"cggv:6cabdaaf-da1c-45c5-9776-66935a54569d","type":"obo:SEPIO_0004097","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"cggv:6cabdaaf-da1c-45c5-9776-66935a54569d_variant_evidence_item"}],"strengthScore":0.1}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:09a38d93-2fea-45e8-aab1-288a42f3babb_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:09a38d93-2fea-45e8-aab1-288a42f3babb","type":"Proband","allele":[{"id":"cggv:e135ad61-2f07-4e85-895e-02c05c6fa9b2","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001111.5(ADAR):c.1630C>T (p.Arg544Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA10575636"}},{"id":"cggv:12a4f790-a00a-43e6-8386-7ee0cf910ff9"}],"detectionMethod":"Sanger sequencing of ADAR was performed on patients","firstTestingMethod":"Sanger sequencing","phenotypes":["obo:HP_0000007","obo:HP_0001332","obo:HP_0002376","obo:HP_0002135"],"sex":"Male","variant":[{"id":"cggv:1c59b819-9d31-4ea6-b949-8219a1cc4002_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:e135ad61-2f07-4e85-895e-02c05c6fa9b2"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/24262145"},{"id":"cggv:df6a46c1-b236-4bb3-81a0-340c697118ce_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:12a4f790-a00a-43e6-8386-7ee0cf910ff9"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/24262145"}],"rdfs:label":"Livingston_3"},{"id":"cggv:1c59b819-9d31-4ea6-b949-8219a1cc4002","type":"obo:SEPIO_0004097","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"cggv:1c59b819-9d31-4ea6-b949-8219a1cc4002_variant_evidence_item"}],"strengthScore":1.5},{"id":"cggv:df6a46c1-b236-4bb3-81a0-340c697118ce","type":"obo:SEPIO_0004097","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:df6a46c1-b236-4bb3-81a0-340c697118ce_variant_evidence_item"},{"id":"cggv:df6a46c1-b236-4bb3-81a0-340c697118ce_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"Yes","dc:description":"Mannion et al. 2014 (PMID: 25456137) found that ADAR p110 and p150 isoform mutants P193A, A870T, R892H, K999N, G1007R, and D1113H expressed in HEK293T cells exhibit a significant decrease in editing activity relative to WT"}],"strengthScore":0.5}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:82af9905-9d2d-4f78-a1f5-5e50941ee88d_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:82af9905-9d2d-4f78-a1f5-5e50941ee88d","type":"Proband","ageType":"AgeAtReport","ageUnit":"Years","ageValue":8,"allele":[{"id":"cggv:6ce0c519-9f29-4e58-b491-039e0c9518d3","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001111.5(ADAR):c.2615T>C (p.Ile872Thr)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA343783"}},{"id":"cggv:12a4f790-a00a-43e6-8386-7ee0cf910ff9"}],"detectionMethod":"Rice et al. used massively parallel sequencing of exomes for probands AGS81_P1 and AGS219 and found variants in ADAR. Then sequenced ADAR in other individuals lacking variants in TREX1, RNASEH2B, RNASEH2C, RNASEH2A and SAMHD1. ","firstTestingMethod":"Other","phenotypes":["obo:HP_0009710","obo:HP_0002415","obo:HP_0000007","obo:HP_0011344","obo:HP_0002376","obo:HP_0002514"],"sex":"Female","variant":[{"id":"cggv:999d798f-1789-4564-a597-cdf437946acb_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:12a4f790-a00a-43e6-8386-7ee0cf910ff9"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/23001123"},{"id":"cggv:fdfdb9f6-5cb9-4fa1-846e-43f8471c7907_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:6ce0c519-9f29-4e58-b491-039e0c9518d3"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/23001123"}],"rdfs:label":"Rice_AGS251"},{"id":"cggv:999d798f-1789-4564-a597-cdf437946acb","type":"obo:SEPIO_0004097","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:999d798f-1789-4564-a597-cdf437946acb_variant_evidence_item"},{"id":"cggv:999d798f-1789-4564-a597-cdf437946acb_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"Yes","dc:description":"Mannion et al. 2014 (PMID: 25456137) found that ADAR p110 and p150 isoform mutants P193A, A870T, R892H, K999N, G1007R, and D1113H expressed in HEK293T cells exhibit a significant decrease in editing activity relative to WT"}],"strengthScore":0.5},{"id":"cggv:fdfdb9f6-5cb9-4fa1-846e-43f8471c7907","type":"obo:SEPIO_0004097","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"cggv:fdfdb9f6-5cb9-4fa1-846e-43f8471c7907_variant_evidence_item"}],"strengthScore":0.1}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:e0ac2b6f-02cc-4fc2-b893-95084abdccc4_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:e0ac2b6f-02cc-4fc2-b893-95084abdccc4","type":"Proband","ageType":"AgeAtReport","ageUnit":"Years","ageValue":14,"allele":[{"id":"cggv:381f2a25-99cd-4acd-9954-063a692b7fa2","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001111.5(ADAR):c.2675G>A (p.Arg892His)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA343773"}},{"id":"cggv:12a4f790-a00a-43e6-8386-7ee0cf910ff9"}],"detectionMethod":"Rice et al. used massively parallel sequencing of exomes for probands AGS81_P1 and AGS219 and found variants in ADAR\n","firstTestingMethod":"Exome sequencing","phenotypes":["obo:HP_0000252","obo:HP_0011344","obo:HP_0001332","obo:HP_0000737","obo:HP_0002415","obo:HP_0000007","obo:HP_0002514"],"sex":"Female","variant":[{"id":"cggv:154480d1-6ea3-4d33-9624-93277dc5b2fe_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:381f2a25-99cd-4acd-9954-063a692b7fa2"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/23001123"},{"id":"cggv:a328b949-a35e-4c95-a273-b30e6616ca94_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:12a4f790-a00a-43e6-8386-7ee0cf910ff9"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/23001123"}],"rdfs:label":"Rice_AGS81"},{"id":"cggv:154480d1-6ea3-4d33-9624-93277dc5b2fe","type":"obo:SEPIO_0004097","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:154480d1-6ea3-4d33-9624-93277dc5b2fe_variant_evidence_item"},{"id":"cggv:154480d1-6ea3-4d33-9624-93277dc5b2fe_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"Yes","dc:description":"Mannion et al. 2014 (PMID: 25456137) found that ADAR p110 and p150 isoform mutants P193A, A870T, R892H, K999N, G1007R, and D1113H expressed in HEK293T cells exhibit a significant decrease in editing activity relative to WT"}],"strengthScore":0.5},{"id":"cggv:a328b949-a35e-4c95-a273-b30e6616ca94","type":"obo:SEPIO_0004097","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:a328b949-a35e-4c95-a273-b30e6616ca94_variant_evidence_item"},{"id":"cggv:a328b949-a35e-4c95-a273-b30e6616ca94_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"Yes","dc:description":"Mannion et al. 2014 (PMID: 25456137) found that ADAR p110 and p150 isoform mutants P193A, A870T, R892H, K999N, G1007R, and D1113H expressed in HEK293T cells exhibit a significant decrease in editing activity relative to WT"}],"strengthScore":0.5}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":12},{"id":"cggv:9cf90ec8-f2fd-4b93-89ca-d20e628a6109_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:9cf90ec8-f2fd-4b93-89ca-d20e628a6109_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:3b413a46-7c3a-4646-a7e7-99cf39673d5c","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:c492765e-3a6a-4e92-8028-0bde68cd117e","type":"Finding","demonstrates":{"id":"obo:MI_0915"},"dc:description":"Authors found that AIMP2 interacted with both ADAR1 and ADAR2 via co-immunoprecipitation, and AIMP2 is also implicated in leukodystrophy","dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/29022589","type":"dc:BibliographicResource","dc:abstract":"Adenosine-to-inosine (A-to-I) RNA editing is a conserved post-transcriptional mechanism mediated by ADAR enzymes that diversifies the transcriptome by altering selected nucleotides in RNA molecules. Although many editing sites have recently been discovered, the extent to which most sites are edited and how the editing is regulated in different biological contexts are not fully understood. Here we report dynamic spatiotemporal patterns and new regulators of RNA editing, discovered through an extensive profiling of A-to-I RNA editing in 8,551 human samples (representing 53 body sites from 552 individuals) from the Genotype-Tissue Expression (GTEx) project and in hundreds of other primate and mouse samples. We show that editing levels in non-repetitive coding regions vary more between tissues than editing levels in repetitive regions. Globally, ADAR1 is the primary editor of repetitive sites and ADAR2 is the primary editor of non-repetitive coding sites, whereas the catalytically inactive ADAR3 predominantly acts as an inhibitor of editing. Cross-species analysis of RNA editing in several tissues revealed that species, rather than tissue type, is the primary determinant of editing levels, suggesting stronger cis-directed regulation of RNA editing for most sites, although the small set of conserved coding sites is under stronger trans-regulation. In addition, we curated an extensive set of ADAR1 and ADAR2 targets and showed that many editing sites display distinct tissue-specific regulation by the ADAR enzymes in vivo. Further analysis of the GTEx data revealed several potential regulators of editing, such as AIMP2, which reduces editing in muscles by enhancing the degradation of the ADAR proteins. Collectively, our work provides insights into the complex cis- and trans-regulation of A-to-I editing.","dc:creator":"Tan MH","dc:date":"2017","dc:title":"Dynamic landscape and regulation of RNA editing in mammals."},"rdfs:label":"Tan_Protein-Protein Interactions"}],"specifiedBy":"GeneValidityProteinInteractionCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":0.5},{"id":"cggv:9cf90ec8-f2fd-4b93-89ca-d20e628a6109_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:98d2a5b6-6e24-4f48-b57e-ce97bf8b4a1d","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:d3ad1c52-bece-4928-a6b0-1158f6bbe68d","type":"Finding","demonstrates":{"id":"cg:PhenotypeRescue"},"dc:description":"They found that short hairpin RNA (shRNA) knockdown of MDA5 rescued proliferation and viability and suppressed ISG induction in hematopoietic stem and progenitor cells expressing only the Adar1E861A allele to control levels, using two independent MDA5 shRNAs.","dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/26275108","type":"dc:BibliographicResource","dc:abstract":"Adenosine-to-inosine (A-to-I) editing is a highly prevalent posttranscriptional modification of RNA, mediated by ADAR (adenosine deaminase acting on RNA) enzymes. In addition to RNA editing, additional functions have been proposed for ADAR1. To determine the specific role of RNA editing by ADAR1, we generated mice with an editing-deficient knock-in mutation (Adar1(E861A), where E861A denotes Glu(861)→Ala(861)). Adar1(E861A/E861A) embryos died at ~E13.5 (embryonic day 13.5), with activated interferon and double-stranded RNA (dsRNA)-sensing pathways. Genome-wide analysis of the in vivo substrates of ADAR1 identified clustered hyperediting within long dsRNA stem loops within 3' untranslated regions of endogenous transcripts. Finally, embryonic death and phenotypes of Adar1(E861A/E861A) were rescued by concurrent deletion of the cytosolic sensor of dsRNA, MDA5. A-to-I editing of endogenous dsRNA is the essential function of ADAR1, preventing the activation of the cytosolic dsRNA response by endogenous transcripts. ","dc:creator":"Liddicoat BJ","dc:date":"2015","dc:title":"RNA editing by ADAR1 prevents MDA5 sensing of endogenous dsRNA as nonself."},"rdfs:label":"Liddicoat_Rescue"}],"specifiedBy":"GeneValidityNonHumanRescueCriteria","strengthScore":2},{"id":"cggv:fdaae8dc-9e77-4c20-89e1-88ddfb534766","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:1c2419de-9f9a-4967-8493-8bb705a5e971","type":"Finding","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"},"dc:description":"Like the human phenotype, Adar1K948N/K948N mice displayed postnatal growth delay, hyperplasia of splenic white pulps with germinal centers and hepatic focal inflammation, lung and heart inflammation with lymphocyte infiltration, and white matter abnormalities with astrocytosis and microgliosis.","dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/34772697","type":"dc:BibliographicResource","dc:abstract":"Aicardi-Goutières syndrome (AGS) is a congenital inflammatory disorder accompanied by overactivated type I IFN signaling and encephalopathy with leukodystrophy and intracranial calcification. To date, none of the mouse models carrying an AGS-causative mutation has mimicked such brain pathology. Here, we established a mutant mouse model carrying a K948N point mutation, corresponding to an AGS-causative K999N mutation, located in a deaminase domain of the ","dc:creator":"Inoue M","dc:date":"2021","dc:title":"An Aicardi-Goutières Syndrome-Causative Point Mutation in "},"rdfs:label":"Inoue_Mouse Model"}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":4}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":4.5}],"evidenceStrength":"Definitive","sequence":9281,"specifiedBy":"GeneValidityCriteria11","strengthScore":16.5,"subject":{"id":"cggv:c04d5607-f7f3-4161-b164-234f9e6301cf","type":"GeneValidityProposition","disease":"obo:MONDO_0700261","gene":"hgnc:225","modeOfInheritance":"obo:HP_0000007"},"version":"1.2","dc:description":"ADAR was first reported in relation to type 1 interferonopathy in 2012 when it was found to be associated with Aicardi-Goutieres syndrome (AGS) (Rice et al., PMID: 23001123), a form of type 1 interferonopathy.  Type 1 interferonopathies are defined as conditions in which increased type 1 interferon signaling leads to autoimmune and neurological disorders (MONDO:0700261). ADAR-related type 1 interferonopathies are seen in both the autosomal recessive and autosomal dominant forms. The autosomal dominant forms of ADAR-related type 1 interferonopathy have been curated separately. \n\nThere are 7 missense, 3 frameshift, and 1 nonsense variants that have been reported in 10 probands in 3 publications (PMIDs: 23001123, 24262145, 29221912) included in this curation. More evidence is available in the literature, but the maximum score for genetic evidence (12 pts.) has been reached. The mechanism of pathogenicity appears to be loss of function. This gene-disease relationship is also supported by rescue studies, protein-protein interactions, and animal models (PMIDs: 26275108, 29022589, 34772697). \n\nIn summary, there is definitive evidence supporting the relationship between ADAR and ADAR-related type 1 interferonopathy, including autosomal recessive Aicardi Goutieres syndrome. This has been repeatedly demonstrated in both the research and clinical diagnostic settings, and has been upheld over time. \n\nThe original curation of the association of ADAR with autosomal recessive Aicardi-Goutieres syndrome (AGS) was approved by the ClinGen Brain Malformations GCEP on the meeting date December 12th, 2023 (SOP Version 9). This gene-disease validity curation was transferred to the Leukodystrophy and Leukoencephalopathy GCEP on October 23, 2024, at which time  the disease entity was changed from “autosomal recessive Aicardi Goutieres syndrome” to the more broad disease entity of “autosomal recessive ADAR-related type 1 interferonopathy,” consistent with other genes that are involved in causing type 1 interferonopathies. \n","dc:isVersionOf":{"id":"cggv:9cf90ec8-f2fd-4b93-89ca-d20e628a6109"},"@context":{"@vocab":"http://dataexchange.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"http://dataexchange.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"http://dataexchange.clinicalgenome.org/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"}}}